# CHARACTERIZATION OF LYMPHOID/MYELOID TRANSFORMING GENE

> **NIH NIH R01** · BARBARA ANN KARMANOS CANCER INSTITUTE · 1989 · $274,186

## Abstract

We previously described five different stage-specific cellular transforming
genes activated in T-\and B-lymphoid leukemias, lymphomas, and myelomas,
which are evolutionarily well-conserved between mouse and man.  These genes
have been detected by transfection of NIH 3T3 cells and analyzed by
restriction endonuclease sensitivity.  A mouse T-lymphoma gene has been
isolated utilizing recombinant DNA technology and is currently being
characterized.  The isolated clone containing the transforming sequence
transforms with high efficiency and it is apparent from current efforts
that the size of the gene is between 1 and 2 kilobases.  This gene, when
used as a molecular probe, appears to identify a small gene family.  In
collaboration with Dr. Geoffrey Cooper's laboratory, utilizing his chicken
bursal gene as a probe, we have isolated a molecular clone containing the
human B lymphoma-transforming sequence.  This gene is the human analogue of
the chicken bursal gene and is the activated cellular transforming gene
which we detect by transfection in human African and American Burkitt's
lymphomas.  The human B-lym gene is not homologous to c-myc, and in
collaboration with Dr. Philip Leder's laboratory, has been localized to
human chromosome 1. Hybridization of this gene to the mouse T-lymphoma gene
indicates that they share no homology. Presently, we are continuing to
isolate and characterize cellular-transforming genes from the lymphoid
series and are further investigating the multistage process of
carcinogenesis.

The T-LymI gene was isolated from the BALB/c mouse T lymphoma S49 and
shares homology with genes encoded in the MHCI region.  The protein encoded
by this gene is 43 to 44 kilodaltons in size and is a secreted protein.
This protein can be immunoprecipitated from the supernates of NIH 3T3 cells
transformed by this gene using antisera cross-reactive with MHCI framework
regions.  Supernates from NIH cells transformed by S49 T-lymphoma DNA and
supernates from the tumor cell line itself stimulate NIH 3T3 cells to form
colonies in semisolid agar.  Preliminary results indicate that the secreted
T-LymI protein may also have a mitotic effect on splenic T lymphocytes in
short-term assays.  This protein shares no homology with IL-2, nor does it
replace IL-2 in IL-2-dependent assays.  (P)

## Key facts

- **NIH application ID:** 3171064
- **Project number:** 7R01CA033108-08
- **Recipient organization:** BARBARA ANN KARMANOS CANCER INSTITUTE
- **SAM.gov UEI:** NAJZPZ4GN5B3
- **Principal Investigator:** MARY-ANN L LANE
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $274,186
- **Award type:** 7
- **Project period:** 1982-08-01 → 1991-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171064

## Citation

> US National Institutes of Health, RePORTER application 3171064, CHARACTERIZATION OF LYMPHOID/MYELOID TRANSFORMING GENE (7R01CA033108-08). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171064. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*